Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse

被引:6
作者
Malkan, Umit Yavuz [1 ]
Gunes, Gursel [1 ]
Yayar, Okan [1 ]
Demiroglu, Haluk [1 ]
机构
[1] Hacettepe Univ, Sch Med, Dept Hematol, TR-0100 Ankara, Turkey
关键词
D O I
10.1155/2015/137682
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Herein, we aimed to report a diffuse large B cell lymphoma (DLBCL) case that had extensive cutaneous relapse with no skin involvement previously. A 59-year-old man presented to hospital in April 2014 with fatigue, anorexia, fever, and anemia. Cervical lymph node biopsy revealed CD20+, BCL2+, MUM1+, BCL6+ high grade B lymphoproliferative neoplasm. After FISH investigation, he was diagnosed as DLBCL. He was given 7 cycles of R-CHOP and achieved remission. However, in November 2014, he had emerging skin lesions that cover nearly all of his body. A control PET-CT revealed diffuse cutaneous involvement. CD20+, BCL2+, MUM1+, BCL6+ high grade B cell lymphoma infiltration was detected with skin biopsy. He was diagnosed as relapse lymphoma, so 2 cycles of R-DHAP were given. There was no treatment response; therefore, R-ICE regimen was started. The patient had achieved second complete remission and his skin lesions were completely regressed. The involvement of skin with CD20+ cells after 7 cycles of rituximab therapy favors that there is a rituximab resistant disease which tends to involve the skin. To conclude, DLBCL may relapse extensively with cutaneous involvement and the best treatment option in these patients is salvage chemotherapy followed by autologous peripheral blood stem cell transplantation.
引用
收藏
页数:3
相关论文
共 16 条
[1]  
Amo Y, 2000, EUR J DERMATOL, V10, P306
[2]   Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma [J].
Cortelazzo, S ;
Rambaldi, A ;
Rossi, A ;
Oldani, E ;
Ghielmin, M ;
Benedetti, F ;
Tarella, C ;
Zaglio, F ;
Vitolo, U ;
Di Nicola, M ;
Pogliani, E ;
Cavalli, F ;
Gianni, AM ;
Barbui, T .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (02) :333-341
[3]   Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma [J].
El-Galaly, T. C. ;
Mylam, Karen Juul ;
Bogsted, Martin ;
Brown, Peter ;
Rossing, Maria ;
Gang, Anne Ortved ;
Haglund, Anne ;
Arboe, Bente ;
Clausen, Michael Roost ;
Jensen, Paw ;
Pedersen, Michael ;
Bukh, Anne ;
Jensen, Bo Amdi ;
Poulsen, Christian Bjorn ;
d'Amore, Francesco ;
Hutchings, Martin .
AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (06) :575-580
[4]   Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era [J].
Gisselbrecht, Christian ;
Glass, Bertram ;
Mounier, Nicolas ;
Gill, Devinder Singh ;
Linch, David C. ;
Trneny, Marek ;
Bosly, Andre ;
Ketterer, Nicolas ;
Shpilberg, Ofer ;
Hagberg, Hans ;
Ma, David ;
Briere, Josette ;
Moskowitz, Craig H. ;
Schmitz, Norbert .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4184-4190
[5]  
Iguchi Tomotaka, 2004, Rinsho Ketsueki, V45, P1129
[6]  
Kerl Helmut, 2001, Keio Journal of Medicine, V50, P269
[7]   Lymphoma Recurrence 5 Years or Later Following Diffuse Large B-Cell Lymphoma: Clinical Characteristics and Outcome [J].
Larouche, Jean-Francois ;
Berger, Francoise ;
Chassagne-Clement, Catherine ;
Ffrench, Martine ;
Callet-Bauchu, Evelyne ;
Sebban, Catherine ;
Ghesquieres, Herve ;
Broussais-Guillaumot, Florence ;
Salles, Gilles ;
Coiffier, Bertrand .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) :2094-2100
[8]   Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population [J].
Liedtke, M. ;
Hamlin, P. A. ;
Moskowitz, C. H. ;
Zelenetz, A. D. .
ANNALS OF ONCOLOGY, 2006, 17 (06) :909-913
[9]   CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy [J].
Massengale, WT ;
McBurney, E ;
Gurtler, J .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (03) :441-443
[10]   Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy [J].
Maurer, Matthew J. ;
Ghesquieres, Herve ;
Jais, Jean-Philippe ;
Witzig, Thomas E. ;
Haioun, Corinne ;
Thompson, Carrie A. ;
Delarue, Richard ;
Micallef, Ivana N. ;
Peyrade, Frederic ;
Macon, William R. ;
Molina, Thierry Jo ;
Ketterer, Nicolas ;
Syrbu, Sergei I. ;
Fitoussi, Olivier ;
Kurtin, Paul J. ;
Allmer, Cristine ;
Nicolas-Virelizier, Emmanuelle ;
Slager, Susan L. ;
Habermann, Thomas M. ;
Link, Brian K. ;
Salles, Gilles ;
Tilly, Herve ;
Cerhan, James R. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) :1066-1073